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Cryptococcal meningitis (CM) is a major cause of death among 
HIV-infected individuals. It causes an estimated 957 900 cases and 
624 700 deaths worldwide annually, the vast majority of them in sub-
Saharan Africa.1 In Cape Town, CM is now the most common cause 
of adult meningitis (63% of all microbiologically confirmed cases2), 
and acute outcomes are poor.3 Even with optimal treatment in study 
settings, 10-week mortality rates are between 24% and 37%.4,5 In 
2009, in a routine care setting at an urban hospital in Johannesburg, 
67% of patients had died or were lost to follow-up at 3 months (N 
Govender et al., unpublished data). Unfortunately almost half of 
South African patients still receive sub-optimal initial treatment with 
oral fluconazole rather than intravenous amphotericin B.3,6 Clearly, 
given the substantial mortality and morbidity associated with CM, 
preventive interventions should be prioritised.
As CM primarily affects patients with CD4+ T-cell counts ≤100 
cells/µl, the incidence should fall during scale-up of antiretroviral 
therapy (ART) programmes, as in the high-income countries.7 
However, despite recent progress in expanding access to ART in 
South Africa,8 the median CD4+ T-cell count of patients initiating 
ART remains low, and a high risk of new AIDS events and mortality 
persists during the first months of ART.9 Numbers of CM cases in 
Cape Town remained constant between 2003 and 2008 despite a large 
increase in ART coverage,10 and national surveillance shows slight 
increases in the incidence of reported CM cases year on year.11
With expanding ART access, an increasing proportion of CM 
diagnoses occur among patients already receiving ART – 20% in 
a cohort of CM patients from Cape Town.12 Most of these patients 
had recently initiated ART (median duration 41 days), and their 
in-hospital mortality was high (29%).12 CM is therefore a leading 
contributor to the high early mortality in African ART programmes. 
It accounts for up to 20% of all deaths,9 many of which are thought to 
be due to ‘unmasking’ cryptococcal disease among patients who had 
sub-clinical disease when starting ART.13,14
To date, preventive strategies have consisted of routine fluconazole 
primary prophylaxis for all patients with low CD4+ T-cell counts. 
Although this approach reduces the incidence of CM,15 concerns 
exist: fluconazole resistance may develop with widespread use;16,17 it 
is not cost-effective;18-21 it is teratogenic; and fluconazole has potential 
interactions with both ART and tuberculosis (TB) medication 
(Table I). These issues have led to very limited uptake of fluconazole 
primary prophylaxis in HIV treatment programmes.
Fortunately, research has demonstrated that nearly all patients 
at risk of developing CM during ART could be identified on entry 
into ART programmes by screening for sub-clinical infection using 
cheap (ZAR38.95), simple and highly sensitive cryptococcal antigen 
(CRAG) blood tests.22 In 707 patients initiating ART in Cape Town, 
stored serum samples from 13% of patients with CD4+ T-cell counts 
≤100 cells/µl tested positive for CRAG in a retrospective analysis. 
Prospective screening for CRAG in this cohort would have been 
100% predictive of subsequent development of CM within the 
first year of treatment.22 If identified prospectively, such patients 
could be given ‘pre-emptive’ treatment to prevent progression from 
cryptococcal antigenaemia to life-threatening meningitis. Such a 
‘targeted’ prevention strategy would avoid many potential problems 
of widespread fluconazole use with a blanket primary prophylaxis 
approach.
Cape Town data also show that 73% of ART-naïve patients 
presenting with CM have already been diagnosed with HIV, a median 
of 4 months before CM, but developed disease before starting ART.23 
CRAG screening could also identify these patients, allowing for 
pre-emptive therapy and fast-tracking for rapid ART initiation – an 
issue of particular priority given the exceptionally high mortality of 
South African patients in this pre-treatment period.24-26 If all patients 
who had previously tested HIV-positive (both those on ART and the 
73% who were known to be HIV-positive but not on ART) had been 
screened, and effective interventions given, up to 78% of cases of CM 
could have been prevented.
CRAG screening directed at all newly diagnosed HIV-positive 
patients with CD4+ T-cell counts ≤100 cells/µl is likely to detect most 
cases. At a programmatic level, plasma from ethylenediaminetetra-
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automatically be tested for CRAG at the laboratory if the CD4+ T-cell 
count was ≤100 cells/µl for the first time in that individual, and in the 
future, development of point-of-care CRAG tests could allow testing 
at the clinic level, greatly simplifying the process.
The optimal treatment of asymptomatic CRAG-positive patients has 
not been studied. Natural history data from Cape Town suggest that 
ART alone is sufficient to clear asymptomatic antigenaemia in around 
50% of cases.22 However, the remaining 50% are at very high risk of 
developing symptomatic CM and death, so proactive management 
is needed. One approach would be to perform lumbar punctures 
for examination of cerebrospinal fluid on all antigenaemic patients 
to assess for CNS involvement. However, this may not be necessary 
among asymptomatic patients, would heavily burden an overstretched 
public health service, and would potentially render a screening 
programme unworkable. A more pragmatic strategy is to treat all 
asymptomatic antigenaemic patients with fluconazole according to 
dosing recommendations in national guidelines: 400 mg daily for 8 
weeks followed by fluconazole 200 mg daily for at least 10 months (or 
until the CD4+ T-cell count rises to >200 cells/µl) and starting ART 
after the initial 2 weeks of fluconazole. Evidence that higher doses 
of fluconazole are more rapidly fungicidal27 may change this dosing 
schedule in future to 800 mg daily for 8 weeks followed by 400 mg daily 
for at least 10 months. However, evidence to support empiric treatment 
of CRAG antigenaemia without CSF analysis is lacking, and studies 
are required. Whether CRAG titres could be used to stratify risk of 
progression to CM and guide treatment decisions and optimal timing 
of ART initiation in such patients must also be defined.
The reduction in morbidity and mortality, and the potential 
economic benefits of a screen-and-treat prevention strategy, are 
substantial.28 In a cohort of South African patients starting ART, 31% 
of inpatient admission days within the first 32 weeks of ART were 
due to CM.29 Each patient admission with CM is estimated to cost 
ZAR20 980 (at 2001 costing).30 A cost-effectiveness analysis in 
Uganda, where CRAG testing costs four times more than in South 
Africa, suggested a cost of only US$190 for each case of CM 
prevented, and US$266 for each life saved.31 Using data from a 
retrospective study of a South African cohort, 52 patients with CD4 
counts <100 cells/µl initiating ART would have to be screened to 
prevent one case of CM.22 At the current cost of ZAR39.85 (National 
Health Laboratory Service tariff), it would cost ZAR2 072 per case 
of CM prevented22 – substantially less than the cost of hospital 
admission. But while evidence for the utility of CRAG screening to 
identify patients at risk of CM is compelling, key questions remain 
of how best to implement a screening policy and how to manage the 
asymptomatic CRAG-positive patients identified.
Further studies are planned to clarify these unresolved questions. 
However, we believe that the strength of the available evidence, 
coupled with the high ongoing mortality secondary to CM among 
South African HIV-positive patients, justifies implementation of 
CRAG screening in the South African HIV programme. This should 
involve a CRAG test on all patients diagnosed with HIV with a CD4+ 
T-cell count ≤100 cells/µl and treating all antigenaemic patients with 
fluconazole.
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Table I. Pros and potential cons of screening for serum 
CRAG among asymptomatic HIV-infected patients with 
CD4+ T-cell count ≤100 cells/µl
Pros Cons
Cryptococcal meningitis is one 
of the most common HIV-
related opportunistic infections 
in South Africa.
If cryptococcosis is diagnosed 
when patients present with 
meningitis:
•    treatment is complex and 
expensive
•   requires 14 days admission
•    mortality is extremely high 
despite optimal treatment.
The cost of a serum CRAG test 
is approximately R40 per test.
Screening asymptomatic patients 
and pre-emptively treating those 
with positive serum CRAG 
to prevent meningitis is cost-
effective.
The optimal treatment of 
patients diagnosed with 
asymptomatic antigenaemia is 
not defined, but we can make 
recommendations pending 
further research.
There are potential drug 
interactions between 
fluconazole and NNRTIs. 
Fluconazole increases 
nevirapine levels, but 
concomitant use has not been 
associated with increased 
nevirapine toxicity in the two 
published studies.32,33
Fluconazole is potentially 
teratogenic, but pregnancy is 
uncommon among patients 
with very low CD4+ T-cell 
counts; this has not been 
reported as a problem where 
primary prophylaxis has been 
used. In an antigen screening 
programme, fluconazole 
exposure would be limited to 
patients at very high risk of 
developing life-threatening CM.
Fluconazole will increase pill 
burden, but is given once a 
day and is well tolerated.
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Deaths during or after a surgical procedure may be considered 
medico-legal and subjected to medico-legal autopsy and inquest. 
We define death in medical terms and discuss the implications of 
the provisions of the Amended Health Professions Act of 1974 and 
its recent amendment. Problems with the old and new definitions 
of such deaths and whether the amendment provides additional 
patient protection for the patient are considered. We challenge the 
South African law-makers to review the all-inclusive terminology in 
relation to such deaths.
Introduction
Patients who undergo anaesthesia and medical procedures may die 
as a result thereof. South African law1 requires any death considered 
unnatural2 to be reported for medico-legal investigation. Unnatural 
death related to anaesthesia is provided for in the Health Professions 
Act.3 In July 2008, a revised version of this statutory obligation 
came into effect with the proclamation of the Health Professions 
Amendment Act.4 We examine the scope and significance of this 
amendment, and consider its implications for health care providers. 
Background and definitions
The repealed law stated that ‘the death of a person whilst under the 
influence of a general anaesthetic or local anaesthetic, or of which the 
administration of an anaesthetic has been a contributory cause, shall 
not be deemed to be a death from natural causes as contemplated 
in the Inquests Act 58 of 1959, or the Births, Marriages and Deaths 
Registration Act 81 of 1963’.3
The amendment provides that ‘the death of a person undergoing, 
or as a result of a procedure of a therapeutic, diagnostic or palliative 
nature, or of which any aspect of such a procedure has been a 
contributory cause, shall not be deemed to be a death from natural 
causes as contemplated in the Inquests Act 58 of 1959, or the Births 
and Deaths Registration Act 51 of 1992’.4
Legislative protection for the anaesthetised patient appeared shortly 
after the introduction of anaesthesia to facilitate invasive surgical 
procedures.5 The drug-induced state of deep unconsciousness and 
loss of voluntary faculties places patients in a position of vulnerability 
to hazards of the anaesthesia, and also in a totally compromised state 
where their lives are subject to the conduct of the health practitioners 
involved. The expectancy of death following procedures performed 
under anaesthesia varies widely, from 1 in 133 patients in Togo to 1 
in 185 000 in the UK, raising concern about anaesthesia and peri-
operative safety in developing countries.6 The peri-operative death 
rate from inpatient surgery in industrialised countries is between 
0.4% and 0.8%, and at least half of all surgical complications may be 
avoidable.7 However, deaths caused by the anaesthetic procedure alone 
account for fewer deaths compared with the surgical procedure itself, 
with mortality associated with general anaesthesia alone ranging from 
0.02%8 reported in Finland, to 0.06%9 reported as a global figure. 
Issues pertinent to South Africa
The amendment in South African law appears to be related to the 
requirement for health professionals to recognise the need for greater 
protection for the vulnerable patient under their authority and care.10 
The wider-ranging provision in section 48 of the Health Professions 
Amendment Act permits legal inquiry into deaths which may have 
evaded investigation under the repealed section 56 of the Health 
Professions Act.Corresponding author: T E Madiba (madiba@ukzn.ac.za)
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